Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)
| Autor: | Michele Senni, Haris Subacius, Umberto Campia, Muthiah Vaduganathan, Aldo P. Maggioni, Javed Butler, Savina Nodari, Faiez Zannad, Sadiya S. Khan, Patrick Rossignol, Marvin A. Konstam, Mihai Gheorghiade, Karl Swedberg, Ovidiu Chioncel |
|---|---|
| Přispěvatelé: | Feinberg School of Medicine, Northwestern University [Evanston], MedStar Heart Institute, MedStar Cardiovascular Research Network, Institute for Cardiovascular Diseases C.C. Iliescu, Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital [Gothenburg], Dalton Cardiovascular Research Center [Columbia], University of Missouri [Columbia] (Mizzou), University of Missouri System-University of Missouri System, Ospedale Papa Giovanni XXIII, Università degli Studi di Brescia [Brescia], Department of Medicine, Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Emory University [Atlanta, GA], Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Khan, S, Campia, U, Chioncel, O, Zannad, F, Rossignol, P, Maggioni, A, Swedberg, K, Konstam, M, Senni, M, Nodari, S, Vaduganathan, M, Subacius, H, Butler, J, Gheorghiade, M |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Hyperkalemia medicine.medical_treatment Potassium Tolvaptan Kaplan-Meier Estimate 030204 cardiovascular system & hematology MESH: Stroke Volume chemistry.chemical_compound 0302 clinical medicine Risk Factors MESH: Risk Factors dipeptidyl carboxypeptidase inhibitor 030212 general & internal medicine MESH: Inpatients MESH: Treatment Outcome MESH: Aged Clinical Trials as Topic Ejection fraction Aldosterone MESH: Middle Aged MESH: Research Design beta adrenergic receptor blocking agent MESH: Follow-Up Studies Middle Aged Hypokalemia 3. Good health Treatment Outcome Research Design Creatinine Aged Antidiuretic Hormone Receptor Antagonists Benzazepines Biomarkers Female Follow-Up Studies Heart Failure Humans Life Expectancy Inpatients Stroke Volume Cardiology MESH: Hyperkalemia MESH: Benzazepines medicine.symptom Cardiology and Cardiovascular Medicine MESH: Life Expectancy medicine.drug medicine.medical_specialty MESH: Clinical Trials as Topic chemistry.chemical_element MESH: Creatinine 03 medical and health sciences [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Internal medicine medicine MESH: Kaplan-Meier Estimate MESH: Humans business.industry medicine.disease MESH: Male angiotensin receptor antagonist chemistry MESH: Hypokalemia Heart failure MESH: Potassium MESH: Heart Failure MESH: Biomarkers Diuretic business MESH: Antidiuretic Hormone Receptor Antagonists MESH: Female aldosterone antagonist |
| Zdroj: | American Journal of Cardiology American Journal of Cardiology, Elsevier, 2015, 115 (6), pp.790-796. ⟨10.1016/j.amjcard.2014.12.045⟩ |
| ISSN: | 0002-9149 1879-1913 |
| DOI: | 10.1016/j.amjcard.2014.12.045⟩ |
| Popis: | International audience; Both hyperkalemia and hypokalemia may be related to heart failure (HF) therapy and are associated with adverse outcomes. Abnormalities in serum potassium levels in hospitalized patients with HF and reduced ejection fraction (EF) have not been previously investigated. A post hoc analysis was performed in 1,907 hospitalized patients with worsening HF and reduced EF in the placebo arm of the Efficacy of Vasopressin Antagonism in HF Outcome Study with Tolvaptan (EVEREST) trial. Serum potassium was measured at randomization and at discharge or day 7. The co-primary end points were all-cause mortality (ACM) and cardiovascular mortality or the first HF hospitalization (CVM + HFH). The association between inhospital change in potassium levels and time to outcomes was evaluated using multivariate Cox regression models. Study participants had a mean age of 65.6 ± 12.0 years and were on optimal guideline-directed medical therapies, including β blockers (77%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (85%), and aldosterone antagonists (55%). Baseline potassium concentration was 4.3 ± 0.6 mEq/l, and hyperkalemia or hypokalemia was seen in 6.5% of the participants. On average, serum potassium level increased by 0.21 ± 0.66 mEq/l, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect